CT103A represents a promising BCMA-directed CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma, with robust clinical efficacy and the potential to address the unmet medical needs of patients with advanced disease. Here, TNFRSF17 is linked to AL amyloidosis.